Physician profile
Abraham A Glazer
NPI 1689699704
$7,994.12
in general payments reported to CMS, 2019-2025
48 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $583 · 2021: $438 · 2022: $811 · 2023: $2,254 · 2024: $1,639 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,221.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,102.30 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $741.91 | 2019-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $466.01 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $452.63 | 2021-2025 | Provenge |
| Pfizer INC. | $428.22 | 2019-2025 | |
| Antares Pharma, INC. | $411.67 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $399.57 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Edap Technomed INC | $398.48 | 2023-2025 | |
| Myriad Genetic Laboratories, INC. | $370.68 | 2020-2024 | Myrisk, Prolaris |
| Abbvie INC. | $292.85 | 2020-2025 | |
| Procept Biorobotics Corporation | $285.49 | 2019-2025 | Aquabeam Robotic System |
| Ferring Pharmaceuticals INC. | $252.62 | 2019-2025 | Adstiladrin |
| Coloplast Corp | $251.35 | 2019-2025 | Speedicath |
| Medtronic, INC. | $204.33 | 2021-2024 | Interstim |
| Tolmar, INC. | $196.69 | 2023-2025 | Jatenzo, Eligard |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$317,482.90 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Glazer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.